A Dark Vector Cognition product

Cover and table of contents

53K characters. Original on sec.gov ·

Cover and table of contents

The 34 tables in Cover and table of contents as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


Form 10-Q


☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33462


INSULET CORPORATION

(Exact name of Registrant as specified in its charter)


Delaware04-3523891
(State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.)
100 Nagog ParkActonMassachusetts01720
(Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: (978) 600-7000


Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per SharePODDThe NASDAQ Stock Market, LLC

As of April 27, 2023, the registrant had 69,695,828 shares of common stock outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements3
Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2023 and December 31, 20223
Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2023 and 20224
Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three months ended March 31, 2023 and 20225
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three months ended March 31, 2023 and 20226
Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2023 and 20227
Notes to Condensed Consolidated Financial Statements (Unaudited)8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 3. Quantitative and Qualitative Disclosures About Market Risk22
Item 4. Controls and Procedures22
PART II. OTHER INFORMATION
Item 1. Legal Proceedings24
Item 1A. Risk Factors24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds24
Item 3. Defaults Upon Senior Securities24
Item 4. Mine Safety Disclosures24
Item 5. Other Information24
Item 6. Exhibits24
Signatures25

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.Condensed Consolidated Financial Statements (Unaudited)

INSULET CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(in millions, except share and per share data)March 31, 2023December 31, 2022
ASSETS
Current Assets
Cash and cash equivalents$620.7$674.7
Accounts receivable trade, less allowance for credit losses of $3.1 and $2.5159.6140.9
Accounts receivable trade, net — related party57.664.7
Inventories386.1346.8
Prepaid expenses and other current assets106.086.9
Total current assets1,330.01,314.0
Property, plant and equipment, net596.6599.9
Other intangible assets, net100.275.5
Goodwill51.751.7
Other assets210.6210.0
Total assets$2,289.1$2,251.1
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable$85.9$30.8
Accrued expenses and other current liabilities263.6301.0
Accrued expenses and other current liabilities — related party6.05.4
Current portion of long-term debt27.827.5
Total current liabilities383.3364.7
Long-term debt, net1,368.81,374.3
Other liabilities34.235.7
Total liabilities1,786.31,774.7
Commitments and contingencies (Note 11)
Stockholders’ Equity
Preferred stock, $.001 par value, 5,000,000 authorized; none issued and outstanding——
Common stock, $.001 par value, 100,000,000 authorized; 69,694,363 and 69,511,286 issued and outstanding0.10.1
Additional paid-in capital1,047.31,040.6
Accumulated deficit(560.5)(584.3)
Accumulated other comprehensive income15.920.0
Total stockholders’ equity502.8476.4
Total liabilities and stockholders’ equity$2,289.1$2,251.1

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

INSULET CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months Ended March 31,
(in millions, except share and per share data)20232022
Revenue$261.3$247.0
Revenue from related party96.848.4
Total revenue358.1295.4
Cost of revenue117.685.7
Gross profit240.5209.7
Research and development expenses50.143.1
Selling, general and administrative expenses162.7128.7
Operating income27.737.9
Interest expense, net(2.9)(8.9)
Other (expense) income, net(0.2)0.3
Income before income taxes24.629.3
Income tax expense(0.8)(1.5)
Net income$23.8$27.8
Net income per share:
Basic$0.34$0.40
Diluted$0.34$0.40
Weighted-average number of common shares outstanding (in thousands):
Basic69,58369,254
Diluted70,09669,858

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

INSULET CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended March 31,
(in millions)20232022
Net income$23.8$27.8
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment1.7(3.7)
Unrealized (loss) gain on cash flow hedges(5.8)18.1
Total other comprehensive (loss) income, net of tax(4.1)14.4
Comprehensive income$19.7$42.2

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

INSULET CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

Three Months Ended March 31, 2023

Common StockAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders’ Equity
(dollars in millions)Shares (in thousands)Amount
Balance at December 31, 202269,511$0.1$1,040.6$(584.3)$20.0$476.4
Exercise of options to purchase common stock110—6.0——6.0
Stock-based compensation expense——12.1——12.1
Restricted stock units vested, net of shares withheld for taxes73—(11.4)——(11.4)
Net income———23.8—23.8
Other comprehensive loss————(4.1)(4.1)
Balance at March 31, 202369,694$0.1$1,047.3$(560.5)$15.9$502.8

Three Months Ended March 31, 2022

Common StockAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive (Loss) IncomeTotal Shareholders’ Equity
(dollars in millions)Shares (in thousands)Amount
Balance at December 31, 202169,179$0.1$1,207.9$(649.5)$(2.2)$556.3
Adoption of ASU 2020-06 (1)——(207.7)60.6—(147.1)
Exercise of options to purchase common stock28—1.1——1.1
Stock-based compensation expense——9.5——9.5
Restricted stock units vested, net of shares withheld for taxes113—(15.3)——(15.3)
Net income———27.8—27.8
Other comprehensive income————14.414.4
Balance at March 31, 202269,320$0.1$995.5$(561.1)$12.2$446.7

(1) The Company recorded a cumulative effect adjustment to additional paid-in capital and retained earnings to reflect the adoption of Accounting Standards Update 2020-06, Debt – Debt With Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Refer to Note 2 of Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2022.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

INSULET CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended March 31,
(in millions)20232022
Cash flows from operating activities
Net income$23.8$27.8
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization17.215.3
Stock-based compensation expense12.19.5
Non-cash interest expense1.51.5
Provision for credit losses1.20.8
Other0.7(0.6)
Changes in operating assets and liabilities:
Accounts receivable(19.2)(19.9)
Accounts receivable — related party7.1(10.1)
Inventories(38.2)(13.0)
Prepaid expenses and other assets(20.7)(6.4)
Accounts payable51.514.7
Accrued expenses and other liabilities(35.9)(33.7)
Accrued expenses and other liabilities — related party(0.6)0.4
Net cash provided by (used in) operating activities0.5(13.7)
Cash flows from investing activities
Capital expenditures(10.5)(12.8)
Investments in developed software(1.5)(3.1)
Acquisition of intangible assets(25.1)—
Acquisition of a business(3.0)(26.0)
Cash paid for investments(2.0)(5.0)
Net cash used in investing activities(42.1)(46.9)
Cash flows from financing activities
Repayment of equipment financings(4.8)(4.3)
Repayment of term loan(1.3)(1.3)
Repayment of mortgage(0.6)(0.5)
Proceeds from exercise of stock options6.01.1
Payment of withholding taxes in connection with vesting of restricted stock units(11.4)(15.3)
Net cash used in financing activities(12.1)(20.3)
Effect of exchange rate changes on cash(0.1)(0.6)
Net decrease in cash, cash equivalents and restricted cash(53.8)(81.5)
Cash, cash equivalents and restricted cash at beginning of period (Note 3)689.7806.4
Cash, cash equivalents and restricted cash at end of period (Note 3**)**$635.9$724.9
Supplemental noncash information:
Purchases of property and equipment included in accounts payable and accrued expenses$5.1$7.8
Purchases of developed software included in accounts payable and accrued expenses$0.8$2.8
Lease liabilities arising from obtaining right-of-use assets$0.1$1.6

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

INSULET CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements reflect the consolidated operations of Insulet Corporation and its subsidiaries (“Insulet” or the “Company”). The unaudited consolidated financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the consolidated financial statements in conformity with GAAP requires management to make use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results may differ from those estimates. In management’s opinion, the unaudited consolidated financial statements contain all normal recurring adjustments necessary for a fair statement of the interim results reported. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2023, or for any other subsequent interim period.

The year-end balance sheet data was derived from audited consolidated financial statements. These unaudited consolidated financial statements do not include all of the annual disclosures required by GAAP; accordingly, they should be read in conjunction with the Company’s audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Related Party Transactions

The Company has a distribution agreement with a related party that contains terms consistent with those prevailing at arm’s length. The spouse of one of the members of the Company’s Board of Directors is an executive officer of the distributor.

Investments

In February 2023, the Company made a $2.0 million strategic investment. As of March 31, 2023 and December 31, 2022, the total carrying value of the Company’s investments primarily recorded at cost less impairment was $10.7 million and $8.7 million, respectively.

Shipping and Handling Costs

Shipping and handling costs included in selling, general and administrative expenses were $2.3 million and $3.1 million for the three months ended March 31, 2023 and 2022, respectively.

Fair Value Measurements

Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. To measure fair value of assets and liabilities, the Company uses the following fair value hierarchy based on three levels of inputs:

Level 1—observable inputs, such as quoted prices in active markets for identical assets or liabilities;

Level 2—significant other observable inputs that are observable either directly or indirectly; and

Level 3—significant unobservable inputs for which there are little or no market data, which require the Company to develop its own assumptions.

Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of their short-term maturity. See Notes 3 and 9 for financial assets and liabilities held at carrying amount on the consolidated balance sheet and Note 10 for derivative instruments measured at fair value on a recurring basis.

Table of Contents

Note 2. Revenue and Contract Acquisition Costs

The following table summarizes the Company’s disaggregated revenue:

Three Months Ended March 31,
(in millions)20232022
U.S. Omnipod$259.0$174.1
International Omnipod98.695.4
Total Omnipod357.6269.5
Drug Delivery0.525.9
Total revenue$358.1$295.4

The percentages of total revenue for customers that represent 10% or more of total revenue were as follows:

Three Months Ended March 31,
20232022
Distributor A28%16%
Distributor B16%13%
Distributor D20%*
  • Represents less than 10% of revenue for the period.

Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown:

(in millions)March 31, 2023December 31, 2022
Accrued expenses and other current liabilities$22.2$16.1
Other liabilities1.71.6
Total deferred revenue$23.9$17.7

Revenue recognized from amounts included in deferred revenue at the beginning of each respective period was as follows:

Three Months Ended March 31,
(in millions)20232022
Deferred revenue recognized$9.9$1.3

Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown:

(in millions)March 31, 2023December 31, 2022
Prepaid expenses and other current assets$16.0$15.2
Other assets33.031.3
Total capitalized contract acquisition costs, net$49.0$46.5

The Company recognized $4.0 million and $3.4 million of amortization of capitalized contract acquisition costs during the three months ended March 31, 2023 and 2022, respectively.

Table of Contents

Note 3. Cash and Cash Equivalents

The following table provides a summary of cash and cash equivalents:

(in millions)March 31, 2023December 31, 2022
Cash$131.2$136.1
Money market mutual funds387.5487.3
Time deposits102.050.8
Restricted cash—0.5
Total cash and cash equivalents620.7674.7
Restricted cash included in other assets15.215.0
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows$635.9$689.7

All cash and cash equivalents are Level 1 in the fair value hierarchy. The restricted cash included in other assets on the consolidated balance sheet is held as a compensating balance against long-term borrowings.

Certain of the Company’s subsidiaries participate in a multi-currency, notional cash pooling arrangement with a third-party bank provider to manage global liquidity requirements. Under this arrangement, cash deposited by participating subsidiaries may be used to offset amounts owed to the bank by other participating subsidiaries to the extent the overall balance in the cash pool is at least zero, providing legal rights of offset. As of March 31, 2023, the Company had a net cash position of approximately $3.1 million, consisting of a gross cash position of approximately $100.3 million less cash borrowings of approximately $97.2 million by participating subsidiaries, which is reflected as cash and cash equivalents in the consolidated balance sheet.

Note 4. Accounts Receivable, Net

At the end of each period, net accounts receivable were comprised of the following:

(in millions)March 31, 2023December 31, 2022
Accounts receivable trade, net$159.2$128.6
Unbilled receivable0.412.3
Accounts receivable, net$159.6$140.9

The percentages of total net accounts receivable trade for customers that represent 10% or more of total net accounts receivable trade were as follows:

March 31, 2023December 31, 2022
Distributor A28%34%
Distributor B13%11%
Distributor D24%23%

Note 5. Inventories

At the end of each period, inventories were comprised of the following:

(in millions)March 31, 2023December 31, 2022
Raw materials$94.2$79.1
Work in process112.384.2
Finished goods179.6183.5
Total inventories$386.1$346.8

Amounts charged to the consolidated statements of operations for excess and obsolete inventory were $2.2 million and $1.1 million for the three months ended March 31, 2023 and 2022, respectively.

Note 6. Cloud Computing Costs

Capitalized costs to implement cloud computing arrangements at cost and accumulated amortization were as follows:

(in millions)March 31, 2023December 31, 2022
Short-term portion$20.0$18.0
Long-term portion95.087.1
Total capitalized implementation costs115.0105.1
Less: accumulated amortization(21.4)(17.1)
Capitalized implementation costs, net$93.6$88.0

Amortization expense is recognized on a straight-line basis over the expected term of the hosting arrangements, which range from three to ten years. Amortization expense was $4.3 million and $1.3 million for the three months ended March 31, 2023 and 2022, respectively.

Note 7. Goodwill and Other Intangible Assets, Net

The carrying amount of goodwill was $51.7 million at both March 31, 2023 and December 31, 2022.

The gross carrying amount, accumulated amortization and net book value of intangible assets at the end of each period were as follows:

March 31, 2023December 31, 2022
(in millions)Gross Carrying AmountAccumulated AmortizationNet Book ValueGross Carrying AmountAccumulated AmortizationNet Book Value
Customer relationships$43.2$(28.3)$14.9$43.2$(27.5)$15.7
Internal-use software36.8(12.5)24.334.8(12.0)22.8
Developed technology27.4(1.5)25.927.4(1.0)26.4
Patents36.1(1.0)35.111.0(0.4)10.6
Total intangible assets$143.5$(43.3)$100.2$116.4$(40.9)$75.5

Amortization expense for intangible assets was $2.4 million and $1.8 million for the three months ended March 31, 2023 and 2022, respectively.

In February 2023, the Company paid Bigfoot Biomedical, Inc. $25.1 million, including transaction costs, to acquire patent assets related to pump-based automated insulin delivery technologies. The acquired patent assets have a useful life of 11 years.

Note 8. Accrued Expenses and Other Current Liabilities

The components of accrued expenses and other current liabilities were as follows:

(in millions)March 31, 2023December 31, 2022
Employee compensation and related costs$55.2$95.9
Accrued rebates82.669.6
Warranty liability - current portion35.057.3
Professional and consulting services33.227.5
Other57.650.7
Accrued expenses and other current liabilities$263.6$301.0

Product Warranty Costs

The Company provides a four-year warranty on Personal Diabetes Managers (“PDMs”) and Controllers sold in the United States and Europe and a five-year warranty on PDMs sold in Canada and may replace Pods that do not function in accordance with product specifications. The Company estimates its warranty obligation at the time the product is shipped based on historical experience and the estimated cost to service the claims. Cost to service the claims reflects the current product cost, reclaim costs, shipping and handling costs and direct and incremental distribution and customer service support costs. Since the Company continues to introduce new products and versions, the anticipated performance of the product over the warranty period is also considered in estimating warranty reserves. Warranty expense is recorded in cost of revenue in the consolidated statements of operations. Reconciliations of the changes in the Company’s product warranty liability were as follows:

Three Months Ended March 31,
(in millions)20232022
Product warranty liability at beginning of period$62.1$6.8
Warranty expense5.53.0
Change in estimate(8.0)—
Warranty fulfillment(20.4)(2.9)
Product warranty liability at the end of period$39.2$6.9

During the fourth quarter of 2022, the Company issued two voluntary medical device correction notices (“MDCs”), one for its Omnipod DASH PDM relating to its battery and the other for its Omnipod 5 Controller relating to its charging port and cable. During the three months ended March 31, 2023, the Company revised the estimated liability for these MDCs by $8.0 million. The change in estimate primarily relates to lower shipping costs for replacement DASH PDMs and lower expected distribution costs for Omnipod 5 Controllers. As of March 31, 2023, the Company had an estimated liability of $31.0 million related to the MDCs included in its product warranty liability.

Note 9. Debt

The components of debt consisted of the following:

(in millions)March 31, 2023December 31, 2022
Revolving Credit Facility expires May 2024$—$—
Equipment financing due May 20247.89.5
Equipment Financing due November 202520.722.5
5.15% Mortgage due November 202565.065.5
0.375% Convertible Senior Notes due September 2026800.0800.0
Term loan due May 2028491.3492.5
Equipment Financing due July 202833.134.4
Unamortized debt discount(7.3)(7.6)
Debt issuance costs(14.0)(15.0)
Total debt, net1,396.61,401.8
Less: current portion27.827.5
Total long-term debt, net$1,368.8$1,374.3

0.375% Convertible Senior Notes

The Company’s 0.375% Convertible Senior Notes due September 2026 (the “Notes”) have an effective interest rate of 0.76%. The Notes are convertible into the Company’s common stock at an initial conversion rate of 4.4105 shares of common stock per $1,000 principal amount of the notes, which is equivalent to a conversion price of $226.73 per share, subject to adjustment under certain circumstances. The notes will be convertible June 1, 2026 through August 28, 2026 by its holders for any reason, and prior to then under certain circumstances.

Additional interest of 0.5% per annum is payable if the Company fails to timely file required documents or reports with the Securities and Exchange Commission (“SEC”). If the Company merges or consolidates with a foreign entity, the Company may be required to pay additional taxes. The Company determined that the higher interest payments and tax payments required in certain circumstances were embedded derivatives that should be bifurcated and accounted for at fair value. The Company assessed the value of the embedded derivatives at each balance sheet date and determined it had nominal value.

In conjunction with the issuance of the Notes, the Company purchased capped calls on the Company’s common stock with certain counterparties to reduce the potential dilution to its common stock (or, in the event the conversion is settled in cash, to provide a source of cash to settle a portion of its cash payment obligation) in the event that at the time of conversion its stock price exceeds the conversion price under the Notes. The capped calls have an initial strike price of $335.90 per share, which represents a premium of 100% over the last reported sale price of the Company’s common stock of $167.95 per share on the date of the transaction. The capped calls cover 3.5 million shares of common stock.

Fair Value of Debt

The carrying amount and the estimated fair value of the Company’s debt were as follows:

March 31, 2023December 31, 2022
(in millions)Carrying ValueEstimated Fair ValueCarrying ValueEstimated Fair Value (1)
Term loan due May 2028(1)$481.4$490.6$482.1$485.1
0.375% Convertible Senior Notes(2)789.61,125.4788.81,038.7
Equipment financings(3)61.661.666.466.4
5.15% Mortgage(3)64.064.064.564.5
Total$1,396.6$1,741.6$1,401.8$1,654.7

(1) Term debt is classified as Level 1 in the fair value hierarchy. Fair value was determined using quoted market prices.

(2) The Notes are classified as Level 2 in the fair value hierarchy. Fair value was determined using the Company’s quoted stock price and the contractual conversion rate.

(3) The equipment financings and mortgage are classified as Level 3 in the fair value hierarchy. The fair values were determined using the cost bases of the financial liabilities, which approximate their carrying values.

Note 10. Derivative Instruments

The Company manages interest rate exposure through the use of interest rate swap transactions with financial institutions acting as principal counterparties. Under the Company’s interest rate swap agreements that expire on April 30, 2025, the Company receives variable rate interest payments and pays fixed interest rates of 0.95% and 0.96% on a total notional value of $480.0 million of its Term Loan. The Company has designated the interest rate swaps as cash flow hedges.

The fair value of interest rate swaps, which are classified as Level 2 in the fair value hierarchy, represent the estimated amounts the Company would receive or pay to terminate the contracts and is determined using industry standard valuation models and market-based observable inputs, including credit risk and interest rate yield curves. The fair value of the interest rate swaps was $31.0 million and $36.9 million at March 31, 2023 and December 31, 2022, respectively, and was included in other assets on the consolidated balance sheets. As of March 31, 2023, the Company estimates that $18.9 million of net gains related to the interest rate swaps included in accumulated other comprehensive income will be reclassified into the statement of operations over the next 12 months. When recognized, gains and losses on cash flow hedges reclassified from accumulated other comprehensive income are recognized within interest expense, net.

Note 11. Commitments and Contingencies

Legal Proceedings

The Company is, from time to time, involved in the normal course of business in various legal proceedings, including intellectual property, contract, employment and product liability suits. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its results of operations.

Note 12. Stock-Based Compensation Expense

Compensation expense related to stock-based awards was recorded as follows:

Three Months Ended March 31,
(in millions)20232022
Cost of revenue$0.1$0.1
Research and development expenses2.82.0
Selling, general and administrative expenses9.27.4
Total$12.1$9.5

Note 13. Accumulated Other Comprehensive Income

Changes in the components of accumulated other comprehensive income, net of tax, were as follows:

Three Months Ended March 31, 2023
(in millions)Foreign Currency Translation AdjustmentUnrealized Gain on Cash Flow HedgesAccumulated Other Comprehensive Income
Balance at beginning of period$(17.0)$37.0$20.0
Other comprehensive income (loss) before reclassifications1.7(1.4)0.3
Amounts reclassified to net income—(4.4)(4.4)
Balance at the end of period$(15.3)$31.2$15.9
Three Months Ended March 31, 2022
(in millions)Foreign Currency Translation AdjustmentUnrealized Gain on Cash Flow HedgesAccumulated Other Comprehensive (Loss) Income
Balance at beginning of period$(6.7)$4.5$(2.2)
Other comprehensive (loss) income before reclassifications(3.7)17.613.9
Amounts reclassified to net income—0.50.5
Balance at the end of period$(10.4)$22.6$12.2

Note 14. Interest Expense, Net

Interest expense, net was as follows:

Three Months Ended March 31,
(in millions)20232022
Cash interest, net of interest rate swaps$8.3$7.9
Accretion of debt discount0.40.4
Amortization of debt issuance costs1.11.1
Capitalized interest(0.4)(0.4)
Interest expense, net of portion capitalized9.49.0
Interest income(6.5)(0.1)
Interest expense, net$2.9$8.9

Note 15. Income Taxes

The Company’s effective tax rate was 3.4% and 5.1% for the three months ended March 31, 2023 and 2022, respectively. Income tax benefits have not been recorded for losses in the United Kingdom where a valuation allowance exists against net deferred tax assets. The Company had a full valuation allowance against its net deferred tax assets in the United Kingdom and the United States at March 31, 2023 and December 31, 2022. The Company had no uncertain tax positions at March 31, 2023 and December 31, 2022.

Note 16. Net Income Per Share

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted net income per share is computed using the weighted average number of common shares outstanding and, when dilutive, common share equivalents. The weighted-average number of common shares used in the computation of basic and diluted net income per share were as follows:

Three Months Ended March 31,
(in thousands)20232022
Weighted average number of common shares outstanding, basic69,58369,254
Stock options394488
Restricted stock units119116
Weighted average number of common shares outstanding, diluted70,09669,858

The number of common share equivalents excluded from the computation of diluted net income per share because either the effect would have been anti-dilutive, or the performance criteria related to the units had not yet been met, were as follows:

Three Months Ended March 31,
(in thousands)20232022
0.375% Convertible Senior Notes due September 20263,5283,528
Restricted stock units238251
Stock options15590
Total3,9213,869

Note 17. Subsequent Event

In May 2023, the Company entered into a $24.0 million financing transaction for manufacturing equipment in Acton, Massachusetts.

Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations